Spyre Therapeutics SYRE
United StatesHealthcare · BiotechnologyUSD
120.21 USD (+48.7%)
14 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Spyre Therapeutics is a clinical-stage biotechnology company developing therapies for immunological diseases, with no approved products or commercial revenue.
Key points
from its scores- ✓Good share-price trend9.8
- ✕Unfavourable risk and backdrop0.0
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
AI analysis
bottom line, main risk, context and newsHigh-risk speculative stock: only suitable for investors with high risk tolerance and a long-term horizon, betting on the success of its pipeline.
Spyre Therapeutics is a pre-revenue biotech company with a liquid balance sheet (current ratio of 18.53) but no profitability (ROE of -22.98), whose value depends on the success of its clinical pipeline and its ability to fund development.
The main risk is the failure of its candidates in clinical trials, which would leave the company worthless and in need of additional financing.
Context and risks
Spyre Therapeutics is a development-stage biotech company with no revenue or approved products, exposing it to inherent regulatory and business model risks. Its balance sheet, with liquidity of 18.53, mitigates short-term financing risk, but the absence of revenue and an ROE of -22.98 reflect dependence on the success of its clinical pipeline and future funding rounds.
Is Spyre Therapeutics stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 7.5 | 4.1 | +82% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 120.21 USD, +48.7% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −23.0
- Price / book
- 7.5
- Market cap
- 7.0B USD
- Enterprise value
- 6.1B USD
Profitability
- ROE
- −23.0%
- ROA
- −19.8%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −89.1M USD
- FCF yield
- −1.3%
Solvency
- Total debt
- 0 USD
- Net debt
- −1.1B USD
- Cash
- 1.1B USD
- Current ratio
- 18.53
- Quick ratio
- 18.23
Growth
- EPS (TTM)
- −1.92 USD
- EPS (forward)
- −3.52 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 3.11
- Analyst consensus
- Strong buy (14)
- Target price
- 120.21 USD
- 52-week range
- 17.65 – 110.17
Recent news
All SYRE news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Spyre Therapeutics
Is Spyre Therapeutics stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 120.21 USD, +48.7% versus the price. This is not investment advice.
What score does Spyre Therapeutics get on MeridIAn Screener?
It scores 1.9 out of 10, rank 2,123 of 2,130 (better than 0% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Risk & Context (0.0). Analysis of 08/10/2026.
How much is Spyre Therapeutics worth on the stock market?
Its market capitalisation is 7.0B USD and its enterprise value, debt included, is 6.1B USD.
How much debt does Spyre Therapeutics have?
It has more cash than debt: net cash of 1.1B USD.
Does Spyre Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Spyre Therapeutics stock performed over the last year?
It has risen 322.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 17.65 and 110.17 USD. Past performance does not guarantee future results.
What do analysts think of Spyre Therapeutics?
14 analysts cover it; their average recommendation is “Strong buy” and their average target is 120.21 USD (+48.7% versus the price). It is an estimate, not market data.